Please login to the form below

Not currently logged in
Email:
Password:

Ironwood Pharmaceuticals

This page shows the latest Ironwood Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

China approves Ironwood Pharma’s IBS treatment

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion.

Latest news

  • AZ’s Sean Bohen to exit after business overhaul; report AZ’s Sean Bohen to exit after business overhaul; report

    Chief commercial officer Mark Mallon has taken on the CEO role at US biotech Ironwood Pharmaceuticals, while Medimmune research head Bahija Jallal agreed to take the helm of UK biotech company

  • AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

    The reshuffle coincides with the departure of two senior leaders: chief commercial officer Mark Mallon, who leaves to become chief executive of US biotech Ironwood Pharmaceuticals, and Bahija Jallal, who leaves

  • Ironwood claims FDA OK for former AZ gout drug Ironwood claims FDA OK for former AZ gout drug

    alone - perhaps modest for AZ but significant for Ironwood which made $274m in total revenues last year. ... according to Ironwood, which has said it intends to launch the drug onto the market in the fourth quarter of this year.

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    AZ previously sold US rights to Zurampic and the follow-up to Ironwood Pharmaceuticals for $265m plus royalties. ... The drug is approved for use alongside xanthine oxidase (XO) inhibitors such as generic allopurinol or Takeda's Uloric (febuxostat) in

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product. ... The licensing agreement gives Ironwood Pharmaceuticals exclusive US rights to Zurampic (lesinurad), which was approved by the FDA in December 2015, as well as a

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    In a "mirror deal" in April this year, AstraZenenca licensed US rights to Zurampic and the fixed dose combination to Ironwood Pharmaceuticals for $100m upfront and up to $165m in further ... collaboration, licence, equity. 73.5. PAION/ Cosmo

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Belgium's TiGenix appoints Dr Gregory Gordon Belgium's TiGenix appoints Dr Gregory Gordon

    Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel. ... Meanwhile, Valles-Sukkar arrives

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Graney most recently spent three years at Ironwood

  • Ironwood Pharmaceuticals appoints chief development officer Ironwood Pharmaceuticals appoints chief development officer

    Dr Christopher Wright joins from Axcella Health. Ironwood Pharmaceuticals has appointed Dr Christopher Wright as its new senior vice president of global development and chief development officer in a role that ... Mark Currie, chief scientific officer

  • Proteostasis Therapeutics strengthens leadership team Proteostasis Therapeutics strengthens leadership team

    James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia. ... Center. Chhabra said: “Geoffrey's extensive experience leading clinical development

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Ironwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors. ... Peter Hecht, CEO of Ironwood, commented on the appointment of Owens: “He has deeply probed the strategy, growth, successes and challenges of nearly every

More from appointments
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics